Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics

Abstract

Narrow-band (NB) UVB and UVA1 have been successfully used for the treatment of atopic dermatitis (AD) since the 1980s, but the clinical indications for their use “at the age of biologics” remain to be assessed. From 2013 to 2017, 145 patients underwent a first treatment cycle with phototherapy. They achieved a median final EASI score of 9.90 with UVA1 and 13.70 with NB-UVB. The rates of patients achieving an IGA score of 0/1 persistent for at least 6 months were 33% with UVA1 and 28% with NB-UVB, and the rates with an EASI90 improvement were 10.9% with UVA1 and 11.0% with NB-UVB. The cut-off baseline EASI values for a good probability to achieve a 0/1 IGA were 24.4 with UVA1 and 24.7 with NB-UVB. A 0/1 IGA persistent for at least 6 months was more likely to be achieved by patients with a history of flares interspersed with periods of mild or no disease. From 2018, we only enrolled patients with the above-mentioned characteristics. The number of treated patients was lower, but the final EASI score, the rate of patients achieving IGA 0/1 persistent for at least 6 months, and EASI90 were significantly higher. Medium-dose UVA1 and NB-UVB phototherapies remain useful for the treatment of AD patients with a baseline EASI score lower than 24.4 and 24.7, respectively, and a medical history of flares followed by prolonged periods of complete or near-complete remission.

Narrowband ultraviolet B phototherapy for pityriasis lichenoides: A real‐life experience

“…In our study, the total cumulative dose and the number of sessions were found to be higher than the studies conducted in dermatoses such as psoriasis and atopic dermatitis reported in the literature. 11,27,28 To the best of our knowledge, there is no study in the literature comparing the efficacy of NB-UVB in pediatric and adult patients with PL. Wahie et al used BB-UVB for eight children and reported that seven (88%) of these children cleared completely or almost cleared of the lesions after phototherapy.…”

External electric field and UV-ozone treated Ti3C2T x -MXene nanosheets and their hole injection tailoring in UV organic light-emitting diodes

“…They have been increasingly used in small and medium-sized electronics such as smartphones, VR/AR displays, and healthy lightings [5][6][7]. Ultraviolet (UV) OLEDs show potential particular applications in medical [8,9], information storage [10], chemical sensing [11], and excitation lighting sources [12]. However, higher energy barrier between anode and organic UV emissive molecule unavoidably leads to higher driving voltage and serious hole-electron imbalance.…”

Editorial: Beyond ultraviolet B radiation: exploring the impact of UVA on skin, reappraisal of UVA phototherapy, and advances in UVA-damage prevention

“…In the last manuscript of this Research Topic, Calzavara-Pinton et al ("The realistic positioning of UVA1 phototherapy after 25 years of clinical experience and the availability of new biologics and small molecules: a retrospective clinical study") have reviewed the clinical results obtained with repeated medium-dose (50J/cm2) exposures to UVA1 (340-400 nm) radiation in a timeframe of 25 years. The clinical uses changed over time on the basis of the clinical efficacy in comparison to NB-UVB and the emergence of new, safe, and effective drugs, biologics and JAK inhibitors, for conditions such as atopic dermatitis and connective tissue disorders (6). At the same time, they found that UVA1 is often ineffective or minimally effective for some uncommon skin diseases, contrary to previous case reports and small case series.…”